Table 4 Multivariate Cox regression... | American Society of Hematology

Table 4

Multivariate Cox regression models for early death, achievement of CR, and disease-free OS for FAB M0 vs FAB M1-M6 among 1277 NPM1^– patients and 564 NPM1^–/CEBPA^– patients with “AML, NOS”

Parameter	Early death^*,†	CR*	RFS*	OS*
NPM1^–
M1-M6	1.03 (0.35-3.03), P = .95	1.19 (0.75-1.91), P = .46	0.98 (0.74-1.31), P = .89	0.91 (0.72-1.16), P = .45
Age	1.04 (1.02-1.06), P < .001	0.96 (0.96-0.97), P < .001	1.02 (1.01-1.02), P < .001	1.03 (1.02-1.03), P < .001
WBC	1.00 (1.00-1.01), P = .11	0.99 (0.99-1.00), P < .001	1.00 (1.00-1.00), P = .096	1.00 (1.00-1.00), P < .001
Platelets	1.00 (0.99-1.00), P = .13	1.00 (1.00-1.00), P = .53	1.00 (1.00-1.00), P = .72	1.00 (1.00-1.00), P = .75
Bone marrow blasts	1.00 (0.99-1.02), P = .062	1.00 (1.00-1.01), P = .49	1.00 (1.00-1.00), P = .46	1.00 (1.00-1.01), P = .14
Male gender	0.81 (0.46-1.44), P = .48	0.78 (0.60-1.03), P = .078	1.14 (0.97-1.34), P = .11	1.06 (0.93-1.22), P = .37
PS = 1	1.74 (0.77-3.95), P = .19	0.77 (0.56-1.06), P = .11	0.97 (0.81-1.17), P = .78	1.09 (0.93-1.27), P = .29
PS ≥ 2	6.02 (2.64-13.72), P < .001	0.54 (0.36-0.81), P = .0034	1.26 (0.98-1.62), P = .069	1.50 (1.23-1.84), P < .001
Abnormal karyotype	1.59 (0.88-2.88), P = .13	0.85 (0.64-1.12), P = .24	1.20 (1.01-1.42), P = .039	1.29 (1.12-1.49), P < .001
NPM1^–/CEBPA^–
M1-M6	0.59 (0.12-2.97), P = .52	1.16 (0.56-2.42), P = .69	1.11 (0.74-1.66), P = .62	1.00 (0.70-1.43), P = .99
Age	1.06 (1.02-1.09), P < .001	0.98 (0.96-0.99), P = .0012	1.01 (1.00-1.01), P = .17	1.02 (1.01-1.03), P < .001
WBC	1.00 (1.00-1.01), P = .35	0.99 (0.99-1.00), P < .001	1.00 (1.00-1.00), P = .25	1.00 (1.00-1.00), P = .0055
Platelets	1.00 (0.99-1.00), P = .66	1.00 (1.00-1.00), P = .098	1.00 (1.00-1.00), P = .21	1.00 (1.00-1.00), P = .066
Bone marrow blasts	1.01 (0.98-1.03), P = .51	1.00 (0.99-1.01), P = .92	1.00 (0.99-1.00), P = .48	1.00 (1.00-1.01), P = .81
Male gender	0.78 (0.31-1.95), P = .60	0.66 (0.43-1.03), P = .067	1.19 (0.95-1.50), P = .13	1.14 (0.93-1.40), P = .20
PS = 1	1.27 (0.35-4.68), P = .71	0.73 (0.44-1.19), P = .21	0.85 (0.66-1.10), P = .22	0.98 (0.78-1.23), P = .87
PS ≥ 2	6.11 (1.75-21.28), P = .0045	0.58 (0.31-1.07), P = .083	1.07 (0.77-1.48), P = .68	1.25 (0.94-1.65), P = .13
Abnormal karyotype	2.34 (0.91-6.04), P = .077	0.89 (0.57-1.38), P = .59	1.07 (0.85-1.35), P = .58	1.21 (1.12-1.49), P = .068

Parameter	Early death^*,†	CR*	RFS*	OS*
NPM1^–
M1-M6	1.03 (0.35-3.03), P = .95	1.19 (0.75-1.91), P = .46	0.98 (0.74-1.31), P = .89	0.91 (0.72-1.16), P = .45
Age	1.04 (1.02-1.06), P < .001	0.96 (0.96-0.97), P < .001	1.02 (1.01-1.02), P < .001	1.03 (1.02-1.03), P < .001
WBC	1.00 (1.00-1.01), P = .11	0.99 (0.99-1.00), P < .001	1.00 (1.00-1.00), P = .096	1.00 (1.00-1.00), P < .001
Platelets	1.00 (0.99-1.00), P = .13	1.00 (1.00-1.00), P = .53	1.00 (1.00-1.00), P = .72	1.00 (1.00-1.00), P = .75
Bone marrow blasts	1.00 (0.99-1.02), P = .062	1.00 (1.00-1.01), P = .49	1.00 (1.00-1.00), P = .46	1.00 (1.00-1.01), P = .14
Male gender	0.81 (0.46-1.44), P = .48	0.78 (0.60-1.03), P = .078	1.14 (0.97-1.34), P = .11	1.06 (0.93-1.22), P = .37
PS = 1	1.74 (0.77-3.95), P = .19	0.77 (0.56-1.06), P = .11	0.97 (0.81-1.17), P = .78	1.09 (0.93-1.27), P = .29
PS ≥ 2	6.02 (2.64-13.72), P < .001	0.54 (0.36-0.81), P = .0034	1.26 (0.98-1.62), P = .069	1.50 (1.23-1.84), P < .001
Abnormal karyotype	1.59 (0.88-2.88), P = .13	0.85 (0.64-1.12), P = .24	1.20 (1.01-1.42), P = .039	1.29 (1.12-1.49), P < .001
NPM1^–/CEBPA^–
M1-M6	0.59 (0.12-2.97), P = .52	1.16 (0.56-2.42), P = .69	1.11 (0.74-1.66), P = .62	1.00 (0.70-1.43), P = .99
Age	1.06 (1.02-1.09), P < .001	0.98 (0.96-0.99), P = .0012	1.01 (1.00-1.01), P = .17	1.02 (1.01-1.03), P < .001
WBC	1.00 (1.00-1.01), P = .35	0.99 (0.99-1.00), P < .001	1.00 (1.00-1.00), P = .25	1.00 (1.00-1.00), P = .0055
Platelets	1.00 (0.99-1.00), P = .66	1.00 (1.00-1.00), P = .098	1.00 (1.00-1.00), P = .21	1.00 (1.00-1.00), P = .066
Bone marrow blasts	1.01 (0.98-1.03), P = .51	1.00 (0.99-1.01), P = .92	1.00 (0.99-1.00), P = .48	1.00 (1.00-1.01), P = .81
Male gender	0.78 (0.31-1.95), P = .60	0.66 (0.43-1.03), P = .067	1.19 (0.95-1.50), P = .13	1.14 (0.93-1.40), P = .20
PS = 1	1.27 (0.35-4.68), P = .71	0.73 (0.44-1.19), P = .21	0.85 (0.66-1.10), P = .22	0.98 (0.78-1.23), P = .87
PS ≥ 2	6.11 (1.75-21.28), P = .0045	0.58 (0.31-1.07), P = .083	1.07 (0.77-1.48), P = .68	1.25 (0.94-1.65), P = .13
Abnormal karyotype	2.34 (0.91-6.04), P = .077	0.89 (0.57-1.38), P = .59	1.07 (0.85-1.35), P = .58	1.21 (1.12-1.49), P = .068

Data are presented as OR or HR (95% CI), as appropriate.

†

Death within 28 d after initiation of therapy or study registration (if exact date of initiation of therapy was unknown).

View Large

This Feature Is Available To Subscribers Only